USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.
Visit United States Adopted Names FAQ to learn more.
Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: [email protected].
In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.
The following names for the drugs described are "under consideration" by the USAN Council:
March 2026
Cagrilintide hydrochloride: Weight management aid
Cliramitug: Treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM) and transthyretin amyloidosis polyneuropathy (ATTR-PN)
Dapiglutide: Treatment of obesity
Deulumateperone: Treatment of psychosis
Deulumateperone tosylate: Treatment of psychosis
Elegrobart: Treatment of thyroid eye disease (TED)
Evarucabgene autoleucel: Treatment of relapsed/refractory AL amyloidosis, with the potential to expand into select immunemediated diseases
Faldoritinib: Treatment of cancer including Acute myeloid leukemia (AML)
Florensocatib: Treatment of non-cystic fibrosis bronchiectasis (NCFBE)
Imeroprubart: Treatment of immunoglobulin (Ig)G-mediated autoimmune diseases
Ixotatug: Antineoplastic
Ixotatug vedotin: Antineoplastic
Lunsotogene parvec: Treatment of OTOF-related congenital hearing loss due to congenital auditory neuropathy
Napazimone: Treatment of primary mitochondrial disease
Ontunisertib: Treatment of inflammatory bowel disease (IBD)
Onvuzosiran: Treatment of hereditary angioedema (HAE)
Onvuzosiran sodium: Treatment of hereditary angioedema (HAE)
Ozureprubart: Treatment of allergic asthma, food allergies, chronic spontaneous urticaria, and other allergic inflammatory diseases
Pegtarazimod: Treatment of hypoxic ischemic encephalopathy (HIE), acute COPD exacerbations, and acute graft vs. host disease
Pegtarazimod hydrochloride: Treatment of hypoxic ischemic encephalopathy (HIE), acute COPD exacerbations, and acute graft vs. host disease
Pevifoscorvir: Treatment of Chronic Hepatitis B Infection; Chronic Hepatitis D Infection
Ponometrep: Treatment of migraine, neuropathic pain, and nociceptive pain
Relzasertideg: Treatment of refractory or recurrent Acute Myeloid Leukemia (AML)
Remlifanserin: Treatment of schizophrenia and the hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP)
Retogatein: Treatment and prevention of autoimmune diabetes, including type 1 diabetes and latent autoimmune diabetes
Rocavorexant: Treatment of opioid use disorder (OUD)
Sevoloprubart: Treatment of autoimmune disorders
Tersolisib: Treatment of HR+, HER2-breast cancer
Zocilurtatug: Antineoplastic, treatment of small-cell lung cancer (SCLC)
February 2026
Atisnolerbart: Treatment of birch pollen allergies
Azamidugene autotemcel: Treatment of Mucopolysaccharidosis type I Hurler (MPS-IH)
Cilotecan: Treatment of advanced/metastatic urothelial carcinoma
Corabotase: Treatment of aesthetic indications and neuromuscular conditions such as spasticity, cervical dystonia as well as sensory neurological conditions
Corubrutinib: Treatment of multiple sclerosis (MS)
Debecarasib: Treatment of advanced solid tumors
Figavetbart: Feline analgesic, treatment of osteoarthritis pain
Flixebrutinib: Treatment of mast cell disorders
Freneslerbart: Treatment of allergic symptoms triggered by cat allergen
Garutadustat: Treatment of inflammatory bowel disease (IBD)
Ignaseclant: Treatment for neuromuscular disorders
Itareparib: Antineoplastic, treatment of solid tumors
Lutetium Lu 177 tezuvotide tetraxetan: Antineoplastic
Mevonlerbart: Treatment of allergic symptoms triggered by cat allergen
Mipitecan: Antineoplastic
Olaviztabart: Treatment of advanced/metastatic urothelial carcinoma
Olaviztabart cilotecan: Treatment of advanced/metastatic urothelial carcinoma
Radiprodil: Anticonvulsant and treatment of GRIN-related neurodevelopmental disorder
Refisolone: Treatment of moderate to severe vasomotor symptoms due to menopause
Silevertinib: Antineoplastic, treatment of glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC)
Sofetabart: Antineoplastic
Sofetabart mipitecan: Antineoplastic
Toviblideg: Treatment of large B cell lymphoma (R/R DLBCL) and follicular lymphoma (R/R FL)
January 2026
Abazistobart: Antineoplastic, treatment of solid tumors
Betovumeline: Treatment of multiple diseases of the central nervous system, including Alzheimer's disease psychosis, schizophrenia, and dyskinesias
Bremzalerbart: Treatment of birch pollen allergies
Cenzestotug: Antineoplastic, treatment of solid tumors
Ciltistotug: Antineoplastic, treatment of solid tumors
Daraxonrasib: Treatment of patients with advanced solid tumors harboring RAS mutations
Elironrasib: Treatment of patients with advanced solid tumors harboring RAS G12C mutations
Esflurbiprofen: Analgesic, anti-inflammatory drug
Etivelcabtagene erigedleucel: Treatment of non-Hodgkin's lymphoma (NHL)
Futermestotug: Antineoplastic, treatment of solid tumors
Gintemetostat: Antineoplastic, treatment of multiple myeloma
Gintemetostat tartrate: Antineoplastic, treatment of multiple myeloma
Imapextide: Treatment of post-bariatric hypoglycemia
Imapextide sodium: Treatment of post-bariatric hypoglycemia
Lasmecabtagene timgedleucel: Treatment of acute lymphoblastic leukemia
Mevonlerbart: Treatment of allergic symptoms triggered by cat allergen
Ramantamig: Antineoplastic, treatment of multiple myeloma
Tralesinidase alfa: Treatment of mucopolysaccharidosis (MPS) type IIIB
Vezocolmitide: Treatment of ophthalmic diseases, disorders, and injuries, including dry eye disease (DED)
Vezocolmitide hydrochloride: Treatment of ophthalmic diseases, disorders, and injuries, including dry eye disease (DED)
Zoldonrasib: Treatment of patients with advanced solid tumors harboring RAS G12D mutations
